ISSN: 1300-0292
İndekslendiği Dizinler: SCIENCE CITATION INDEX EXPANDED
CINAHL, Index Copernicus,
Chemical Abstracts (CA),
Excerpta Medica / EMBASE
Dil: Türkçe, İngilizce
İçerik: Orijinal Araştırma, Derleme, Editöre Mektup, Olgu Sunumu, Tıp Eğitimi, Tıbbi Kitap İncelemeleri
|
|
|
|
ORIGINAL RESEARCH ARTICLES |
Assessment Of Safety And Efficacy Of Levosimendan Therapy On Symptomatic Relief Acute Decompansated Heart Failure
Dr. Dursun ARAS, aDr. Serkan TOPALOĞLU, aDr. Gökhan CİHAN, aDr. Bülent DEVECİ, aDr. Özcan ÖZEKE, aDr. Orhan MADEN, aDr. Ali YILDIZ, aDr. Göksel ÇAĞIRCI, aDr. Ahmet AKGÜL, bDr. Halil KISACIK, aDr. Şule KORKMAZa
aKardiyoloji Kliniği, bKalp ve Damar Cerrahisi Kliniği, Türkiye Yüksek İhtisas Eğitim ve Araştırma Hastanesi, ANKARA
Objective: Calcium sensitizers constitute a new class of drugs that offer hemodynamic, symptomatic and survival benefits in patients with acute decompansated heart failure. Levosimendan is the most potent calcium-sensitizing drug with vasodilator and inotropic effects. The aim of this study was to evaluate the safety and efficacy on symptomatic relief of levosimendan therapy in acute decompansated heart failure.
Material and Methods: The study included 49 patients (36 male, mean age 56 ± 17 year) who had received levosimendan therapy. Following a 12 or 24 μg/kg/10 minute loading dose of levosimendan, 0.05-0.2 μg/kg/minute infusion for 24 hr was planned. At the end of treatment the change in symptomatic status, side effects attributed to levosimendan therapy and New York Heart Association (NYHA) functional class at the time of discharge were assessed.
Results: At the end of levosimendan therapy improvement in symptoms were observed in 36 (71%) patients; 1 (2%) patient showed symptomatic deterioration and in 13 (27%) patients no change in symptomatic status was observed. Significant improvement in NYHA functional status was detected at the time of discharge compared to pretreatment status (NYHA class 2.6 vs. class 3.3, p< 0.001). During the treatment period, the most common side effects were hypotension (14%), non-sustained ventricular tachycardia (12%) and headache (8%). Treatment was withdrawn due to adverse events in 2 (4%) patients. While no deaths were observed during the treatment period; 2 patients-one 2 days and the other 2 weeks after the therapy-during the hospital stay.
Conclusion: In the majority of acute decompansated heart failure patients, symptomatic improvement was achieved with levosimendan therapy with acceptable tolerability. Levosimendan therapy may become more popular in severe congestive heart failure treatment if the beneficial effects can be confirmed in ongoing large-scale studies.Keywords: Calcium, levosimendan, heart failureTurkiye Klinikleri J Med Sci 2006, 26:31-36
|
|
|
|
|
